Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel life-altering therapeutics for rare and often fatal diseases. The Company’s lead product, lomitapide, is a first-in-class, small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. Aegerion submitted a New Drug Application to the FDA, and an Marketing Authorization Application to the EMA, in the first quarter of 2012. The Company also plans to initiate a clinical program to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC).